EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Vaginal micronised progesterone for the prevention of hypertensive disorders of pregnancy: A systematic review and meta‐analysis

Pedro Melo iD, Adam Devall, Andrew H Shennan, Manu Vatish, Christian M Becker, Ingrid Granne, Aris T Papageorghiou, Ben W Mol iD, Arri Coomarasamy

BJOG: An International Journal of Obstetrics & Gynaecology · 2024-05 · 131 (6) · 727-739

DOI: 10.1111/1471-0528.17705 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, online erschienen am 08.11.2023. Verfasst von Pedro Melo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Progesterone, Hypertension, Pregnancy-Induced. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment with vaginal progesterone reduces the risk of miscarriage and preterm birth in selected high‐risk women. The hypothesis that vaginal progesterone can reduce the risk of hypertensive disorders of pregnancy (HDP) is unexplored.

Objectives

To summarise the evidence on the effectiveness of vaginal progesterone to reduce the risk of HDP. Search strategy We searched Embase (OVID), MEDLINE (OVID), PubMed, CENTRAL and clinicaltrials.gov from inception until 20 June 2023. Selection criteria We included placebo‐controlled randomised trials (RCTs) of vaginal progesterone for the prevention or treatment of any pregnancy complications. Data collection and analysis We extracted absolute event numbers for HDP and pre‐eclampsia in women receiving vaginal progesterone or placebo, and meta‐analysed the data with a random effects model. We appraised the certainty of the evidence using GRADE methodology. Main results The quantitative synthesis included 11 RCTs, of which three initiated vaginal progesterone in the first trimester, and eight in the second or third trimesters. Vaginal progesterone started in the first trimester of pregnancy lowered the risk of any HDP (risk ratio [RR] 0.71, 95% confidence interval [CI] 0.53–0.93, 2 RCTs, n = 4431 women, I 2 = 0%; moderate‐certainty evidence) and pre‐eclampsia (RR 0.61, 95% CI 0.41–0.92, 3 RCTs, n = 5267 women, I 2 = 0%; moderate‐certainty evidence) when compared with placebo. Vaginal progesterone started in the second or third trimesters was not associated with a reduction in HDP (RR 1.19, 95% CI 0.67–2.12, 3 RCTs, n = 1602 women, I 2 = 9%; low‐certainty evidence) or pre‐eclampsia (RR 0.97, 95% CI 0.71–1.31, 5 RCTs, n = 4274 women, I 2 = 0%; low‐certainty evidence).

Conclusions

Our systematic review found first‐trimester initiated vaginal micronised progesterone may reduce the risk of HDP and pre‐eclampsia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProgesteroneHypertension, Pregnancy-InducedHumansFemalePregnancyAdministration, IntravaginalProgestinsRandomized Controlled Trials as TopicPre-Eclampsia

Stichwörter der Autor:innen

hypertensive disorders of pregnancypre‐eclampsiaprogesterone

Substanzen

ProgesteroneProgestins

Autor:innen und Institutionen

  • Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK.
  • Tommy's National Centre for Miscarriage Research, College of Medical and Dental Sciences, Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, UK.
  • Department of Women and Children's Health, King's College London, London, UK.
  • Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia.
  • Aberdeen Centre for Women's Health Research, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.

ORCID-Profile: Pedro Melo, Ben W Mol

Zitieren

APA

Melo, P., Devall, A., Shennan, A. H., Vatish, M., Becker, C. M., Granne, I., Papageorghiou, A. T., Mol, B. W., & Coomarasamy, A. (2024). Vaginal micronised progesterone for the prevention of hypertensive disorders of pregnancy: A systematic review and meta‐analysis. BJOG: An International Journal of Obstetrics & Gynaecology, 131(6), 727-739. https://doi.org/10.1111/1471-0528.17705

Vancouver

Melo P, Devall A, Shennan AH, Vatish M, Becker CM, Granne I, et al. Vaginal micronised progesterone for the prevention of hypertensive disorders of pregnancy: A systematic review and meta‐analysis. BJOG: An International Journal of Obstetrics & Gynaecology. 2024;131(6):727-739. doi:10.1111/1471-0528.17705

BibTeX
@article{Melo2024,
  author = {Melo, Pedro and Devall, Adam and Shennan, Andrew H and Vatish, Manu and Becker, Christian M and Granne, Ingrid and Papageorghiou, Aris T and Mol, Ben W and Coomarasamy, Arri},
  title = {Vaginal micronised progesterone for the prevention of hypertensive disorders of pregnancy: A systematic review and meta‐analysis},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2024},
  volume = {131},
  number = {6},
  pages = {727--739},
  doi = {10.1111/1471-0528.17705}
}
Kostenlos starten →